These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 26542659)

  • 21. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 12: Emergency Action Plans, Resuscitation, Cardiopulmonary Resuscitation, and Automated External Defibrillators: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Link MS; Myerburg RJ; Estes NAM
    J Am Coll Cardiol; 2015 Dec; 66(21):2434-2438. PubMed ID: 26542665
    [No Abstract]   [Full Text] [Related]  

  • 22. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Udelson JE; Bonow RO; Nishimura RA; Ackerman MJ; Estes NAM; Cooper LT; Link MS; Maron MS
    J Am Coll Cardiol; 2015 Dec; 66(21):2362-2371. PubMed ID: 26542657
    [No Abstract]   [Full Text] [Related]  

  • 23. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Zipes DP; Link MS; Ackerman MJ; Kovacs RJ; Myerburg RJ; Estes NA;
    Circulation; 2015 Dec; 132(22):e315-25. PubMed ID: 26621650
    [No Abstract]   [Full Text] [Related]  

  • 24. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, and Impact: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Levine BD; Baggish AL; Kovacs RJ; Link MS; Maron MS; Mitchell JH
    J Am Coll Cardiol; 2015 Dec; 66(21):2350-2355. PubMed ID: 26542656
    [No Abstract]   [Full Text] [Related]  

  • 25. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Braverman AC; Harris KM; Kovacs RJ; Maron BJ
    J Am Coll Cardiol; 2015 Dec; 66(21):2398-2405. PubMed ID: 26542664
    [No Abstract]   [Full Text] [Related]  

  • 26. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Braverman AC; Harris KM; Kovacs RJ; Maron BJ;
    Circulation; 2015 Dec; 132(22):e303-9. PubMed ID: 26621648
    [No Abstract]   [Full Text] [Related]  

  • 27. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Udelson JE; Bonow RO; Nishimura RA; Ackerman MJ; Estes NA; Cooper LT; Link MS; Maron MS;
    Circulation; 2015 Dec; 132(22):e273-80. PubMed ID: 26621644
    [No Abstract]   [Full Text] [Related]  

  • 28. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Ackerman MJ; Zipes DP; Kovacs RJ; Maron BJ;
    Circulation; 2015 Dec; 132(22):e326-9. PubMed ID: 26527716
    [No Abstract]   [Full Text] [Related]  

  • 29. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 12: Emergency Action Plans, Resuscitation, Cardiopulmonary Resuscitation, and Automated External Defibrillators: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Link MS; Myerburg RJ; Estes NA;
    Circulation; 2015 Dec; 132(22):e334-8. PubMed ID: 26621652
    [No Abstract]   [Full Text] [Related]  

  • 30. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Zipes DP; Kovacs RJ
    J Am Coll Cardiol; 2015 Dec; 66(21):2343-2349. PubMed ID: 26542655
    [No Abstract]   [Full Text] [Related]  

  • 31. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, and Impact: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Levine BD; Baggish AL; Kovacs RJ; Link MS; Maron MS; Mitchell JH;
    Circulation; 2015 Dec; 132(22):e262-6. PubMed ID: 26621643
    [No Abstract]   [Full Text] [Related]  

  • 32. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 4: Congenital Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Van Hare GF; Ackerman MJ; Evangelista JA; Kovacs RJ; Myerburg RJ; Shafer KM; Warnes CA; Washington RL;
    Circulation; 2015 Dec; 132(22):e281-91. PubMed ID: 26621645
    [No Abstract]   [Full Text] [Related]  

  • 33. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Jacobs AK; Anderson JL; Halperin JL
    J Am Coll Cardiol; 2014 Sep; 64(13):1373-84. PubMed ID: 25103073
    [No Abstract]   [Full Text] [Related]  

  • 34. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.
    Jacobs AK; Anderson JL; Halperin JL; ; Anderson JL; Halperin JL; Albert NM; Bozkurt B; Brindis RG; Curtis LH; DeMets D; Fleisher LA; Gidding S; Hochman JS; Kovacs RJ; Ohman EM; Pressler SJ; Sellke FW; Shen WK; Wijeysundera DN
    Circulation; 2014 Sep; 130(14):1208-17. PubMed ID: 25092464
    [No Abstract]   [Full Text] [Related]  

  • 35. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.
    Maron BJ; Thompson PD; Ackerman MJ; Balady G; Berger S; Cohen D; Dimeff R; Douglas PS; Glover DW; Hutter AM; Krauss MD; Maron MS; Mitten MJ; Roberts WO; Puffer JC;
    Circulation; 2007 Mar; 115(12):1643-455. PubMed ID: 17353433
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.
    ; ; ; ; Wann LS; Curtis AB; Ellenbogen KA; Estes NA; Ezekowitz MD; Jackman WM; January CT; Lowe JE; Page RL; Slotwiner DJ; Stevenson WG; Tracy CM; Fuster V; Rydén LE; Cannom DS; Crijns HJ; Curtis AB; Ellenbogen KA; Halperin JL; Le Heuzey J; Kay GN; Lowe JE; Olsson SB; Prystowsky EN; Tamargo JL; Wann LS
    Circulation; 2013 May; 127(18):1916-26. PubMed ID: 23545139
    [No Abstract]   [Full Text] [Related]  

  • 37. Profile of preparticipation cardiovascular screening for high school athletes.
    Glover DW; Maron BJ
    JAMA; 1998 Jun; 279(22):1817-9. PubMed ID: 9628714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.
    Anderson JL; Heidenreich PA; Barnett PG; Creager MA; Fonarow GC; Gibbons RJ; Halperin JL; Hlatky MA; Jacobs AK; Mark DB; Masoudi FA; Peterson ED; Shaw LJ
    J Am Coll Cardiol; 2014 Jun; 63(21):2304-22. PubMed ID: 24681044
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessment of the 12-lead electrocardiogram as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 years of age): a scientific statement from the American Heart Association and the American College of Cardiology.
    Maron BJ; Friedman RA; Kligfield P; Levine BD; Viskin S; Chaitman BR; Okin PM; Saul JP; Salberg L; Van Hare GF; Soliman EZ; Chen J; Matherne GP; Bolling SF; Mitten MJ; Caplan A; Balady GJ; Thompson PD; ; ; ; ; ; ;
    J Am Coll Cardiol; 2014 Oct; 64(14):1479-514. PubMed ID: 25234655
    [No Abstract]   [Full Text] [Related]  

  • 40. Insights into the AHA scientific statement concerning cardiovascular preparticipation screening of competitive athletes.
    McGrew CA
    Med Sci Sports Exerc; 1998 Oct; 30(10 Suppl):S351-3. PubMed ID: 9789861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.